Over the first half of the fourth quarter, Levocetirizine DiHydrochloride prices gradually increased in North America. The pharmaceutical industry's end-user demand kept Levocetirizine Di-Hydrochloride costs on the high end. Additionally, there was a steep decline in supply chain disruption in the six months leading up to November across several measures, including shipping costs, which further bolstered the Levocetirizine Di-Hydrochloride market's upward trend. However, at the beginning of December, they started to fall precipitously due to a major decrease in their offtakes. Prices for Levocetirizine Di-Hydrochloride declined when they were recorded at USD 648000 /MT CFR Los Angeles.
In the fourth quarter of 2022, Levocetirizine DiHydrochloride prices in Asia, particularly in China, sharply declined. However, prices remained good throughout the initial half of q4 due to strong downstream demand balanced with supplies among market participants. On the other hand, the ease with which the supply chain was disrupted in November compared to October, including the lower shipping costs, encouraged the traders and suppliers to increase orders and balance the demand side. With the year 2022 concluding, China's production activities started to notably decline after November due to an increase in COVID-19 instances, which caused a decline in trade momentum and a reduction in freight costs, both of which helped the Levocetirizine Di-Hydrochloride price trend. Overall, the Levocetirizine Di-Hydrochloride costs noted in the middle of the fourth were assembled at USD 604500/MT FOB Shanghai in China.
The Levocetirizine Di-Hydrochloride market in Europe followed a similar trajectory to that in Asia Pacific in the fourth quarter of 2022. Due to a rise in demand from the end-user pharmaceutical business, the market trend started off well up until November and reached an assembly price of USD 663990/MT CFR Hamburg in Germany. Until December, Levocetirizine Di-Hydrochloride pricing inquiries from the downstream industry remained sturdy, reinforcing the drug's weaker price trend because market participants had plenty of supply and little demand. Furthermore, fresher orders did not require by traders as suppliers had enough stocks with them to meet any immediate necessities.
ChemAnalyst tackles the primary difficulty areas of the worldwide chemical, petroleum, pharmaceutical, and petrochemical industries, empowering decision-makers to make informed decisions. It examines and analyses geopolitical risks, environmental concerns, raw material availability, supply chain functioning, and technological disruption. It focuses on market volatility and guarantees that clients manage obstacles and hazards effectively and efficiently. ChemAnalyst's primary expertise has been data timeliness and accuracy, benefiting both local and global industries by tuning in to real-time data points to execute multibillion-dollar projects internationally.